💉 A medical experiment cures type 1 diabetes

It may be possible to treat type 1 diabetes simply by re-educating the immune system. Researchers at Stanford Medicine have achieved this feat in mice, opening up hope for numerous autoimmune diseases. Their approach combines two transplants to restore insulin production without using medications, an advancement that could transform patient care.

For this experiment, scientists worked with mice with autoimmune diabetes similar to the human form. They simultaneously transplanted blood stem cells and insulin-producing pancreatic islet cells from a non-compatible donor. This double transplant not only allowed the replacement of destroyed cells but also modified the body's immune response. Consequently, the animals regained normal blood sugar regulation for the entire duration of the study.


The success of this method relies on creating a hybrid immune system, where donor and recipient cells coexist. This original configuration prevents autoimmune attacks against the new pancreatic cells. Notably, no mice developed graft-versus-host disease, a common risk in transplants. The researchers indicate that this coexistence teaches the immune system to tolerate the transplanted tissues and to stop attacking the body.

To prepare the mice for the transplant, a milder procedure was used, including antibodies, a medication for autoimmune diseases, and a low dose of radiation. These elements are already used clinically for other treatments, which could facilitate a later application in humans. According to the authors, this preparation reduces side effects and makes the technique safer, even for non-cancerous conditions like diabetes.

The implications of this work extend beyond diabetes. This approach could indeed benefit other autoimmune diseases, such as rheumatoid arthritis or lupus, as well as organ transplants. The researchers also envision its use for certain blood disorders like sickle cell anemia. Their results are built upon decades of immunology research, with the goal of making stem cell transplants accessible to a broader range of patients.

Some obstacles remain, particularly the limited availability of pancreatic islet cells, which can only be obtained after a donor's death. To overcome this difficulty, solutions are being studied, such as producing these cells in the laboratory from human stem cells. Future studies will need to confirm efficacy and safety in humans, but these initial results pave the way for new therapies.

Seung K. Kim, lead author of the study published in The Journal of Clinical Investigation, notes that the key steps of this protocol are already practiced in human medicine. This convergence between basic research and clinical applications could accelerate the development of curative treatments, thereby changing the management of autoimmune diseases and transplants.